Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
IRBESARTAN
Dexcel-Pharma Limited
75 Milligram
Film Coated Tablet
2012-02-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Irbesartan Dexcel 75 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 75 mg of irbesartan For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet White, film-coated, oval shaped tablets. The dimensions are approximately 10.7 x 6.0 mm 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive product regimen (see section 5.1) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Method of administration Oral use The tablets should be swallowed with a glass of liquid, with or without food. Posology The usual recommended initial and maintenance dose is 150 mg once daily. Irbesartan tablets at a dose of 150 mg once daily generally provide a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan tablets can be increased to 300 mg, or other antihypertensive agents can be added. In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Irbesartan tablets (see section 4.5). In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. The demonstration of renal benefit of Irbesartan tablets in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to Les hele dokumentet